Presentation and Webcast on Thursday, June 5 at 2:30 p.m. Eastern Time
ANN ARBOR, Mich.--(BUSINESS WIRE)--
Esperion Therapeutics Inc. (NASDAQ:ESPR), a clinical stage
biopharmaceutical company focused on developing and commercializing
first-in-class, oral, low-density lipoprotein cholesterol (LDL-C)
lowering therapies for the treatment of patients with
hypercholesterolemia and other cardiometabolic risk markers, today
announced the Company will present at the Jefferies 2014 Global
Healthcare Conference in New York City, N.Y. Tim M. Mayleben, president
and chief executive officer, will provide an update on the company on
Thursday, June 5 at 2:30 p.m. Eastern Time.
A live, listen-only webcast of the presentation can be accessed on the
investor relations section of the Esperion website at www.esperion.com.
A webcast replay of the call will be available approximately one hour
after completion of the call and will be archived on the Company's
website for 90 days following the event.
About Esperion Therapeutics
Esperion Therapeutics, Inc. is a clinical stage biopharmaceutical
company focused on developing and commercializing first-in-class, oral,
LDL-cholesterol lowering therapies for the treatment of patients with
hypercholesterolemia and other cardiometabolic risk markers. ETC-1002,
Esperion's lead product candidate, is a unique, first-in-class, orally
available, once-daily small molecule designed to lower LDL-cholesterol
levels and avoid the side effects associated with the currently
available LDL-cholesterol lowering therapies. ETC-1002 is being
developed primarily for patients intolerant of statins with elevated
levels of LDL-cholesterol. Phase 2b clinical trials for ETC-1002 are
currently underway and build upon a successful and comprehensive Phase 1
and Phase 2 program. For more information, please visit www.esperion.com
and follow us on Twitter at https://twitter.com/EsperionInc.
Source: Esperion Therapeutics Inc.